Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
161.3 USD | +0.37% | -0.71% | +4.26% |
03:43pm | AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders | MT |
09/05 | Medincell: share price rises on resumption of trading | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.26% | 284B | |
+30.00% | 684B | |
+30.34% | 568B | |
-3.96% | 361B | |
+18.25% | 329B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+6.87% | 166B | |
-1.45% | 159B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Goldman Sachs Adjusts Price Target on AbbVie to $180 From $173, Keeps Buy Rating